All Stories

  1. Semi-Quantitative Ultrasonographic Evaluation of NAFLD
  2. History of Nonalcoholic Fatty Liver Disease
  3. NAFLD in Some Common Endocrine Diseases: Prevalence, Pathophysiology, and Principles of Diagnosis and Management
  4. A critical appraisal of the use of ultrasound in hepatic steatosis
  5. Telomere shortening: An innocent bystander at the crossroad of NASH with ageing and cardiometabolic risk?
  6. Do Nonalcoholic Fatty Liver Disease and Fetuin-A Play Different Roles in Symptomatic Coronary Artery Disease and Peripheral Arterial Disease?
  7. NAFLD: Is There Anything New under the Sun?
  8. Ultrasonographic fatty liver indicator detects mild steatosis and correlates with metabolic/histological parameters in various liver diseases
  9. Nonalcoholic fatty liver disease and COPD. Are they mutually associated ?
  10. Metabolic concerns in aging HIV-infected persons
  11. NAFLD as a Sexual Dimorphic Disease: Role of Gender and Reproductive Status in the Development and Progression of Nonalcoholic Fatty Liver Disease and Inherent Cardiovascular Risk
  12. AISF position paper on nonalcoholic fatty liver disease (NAFLD): Updates and future directions
  13. NAFLD, Hepatotropic Viruses, and Cardiometabolic Risk
  14. “ Not all forms of NAFLD were created equal ”. Do metabolic syndrome-related NAFLD and PNPLA3 -related NAFLD exert a variable impact on the risk of early carotid atherosclerosis?
  15. Clinical features and natural history of cryptogenic cirrhosis compared to hepatitis C virus-related cirrhosis
  16. Nonalcoholic steatohepatitis heralding olmesartan-induced sprue-like enteropathy
  17. Non-alcoholic fatty liver disease and risk of incident cardiovascular disease: A meta-analysis
  18. Non-alcoholic fatty liver disease and risk of cardiovascular disease
  19. Alcohol and Steatosis: The Japanese Paradox
  20. Global epidemiology of nonalcoholic fatty liver disease: Meta-analytic assessment of prevalence, incidence, and outcomes
  21. Nonalcoholic fatty liver disease is associated with an almost twofold increased risk of incident type 2 diabetes and metabolic syndrome. Evidence from a systematic review and meta-analysis
  22. The independent predictors of non-alcoholic steatohepatitis and its individual histological features.
  23. Type 2 Diabetes in Non-Alcoholic Fatty Liver Disease and Hepatitis C Virus Infection—Liver: The “Musketeer” in the Spotlight
  24. A “systems medicine” approach to the study of non-alcoholic fatty liver disease
  25. The Role of Nuclear Receptors in the Pathophysiology, Natural Course, and Drug Treatment of NAFLD in Humans
  26. Relationship between Non-Alcoholic Fatty Liver Disease and Psoriasis: A Novel Hepato-Dermal Axis?
  27. Nonalcoholic Fatty Liver Disease Is Associated With Higher 1-year All-Cause Rehospitalization Rates in Patients Admitted for Acute Heart Failure
  28. Cardiovascular Disease and Myocardial Abnormalities in Nonalcoholic Fatty Liver Disease
  29. Fatty liver is associated with an increased risk of diabetes and cardiovascular disease - Evidence from three different disease models: NAFLD, HCV and HIV
  30. Gamma glutamyl transferase: A novel cardiovascular outfit for an old liver test
  31. Epidemiological modifiers of non-alcoholic fatty liver disease: Focus on high-risk groups
  32. Sofosbuvir-based therapy cures hepatitis C virus infection after prior treatment failures in a patient with concurrent lymphoma
  33. Evidence that non-alcoholic fatty liver disease and polycystic ovary syndrome are associated by necessity rather than chance: a novel hepato-ovarian axis?
  34. Nonalcoholic fatty liver disease and decreased bone mineral density: is there a link?
  35. Do ultrasonographic semiquantitative indices predict histological changes in NASH irrespective of steatosis extent?
  36. Nonalcoholic fatty liver disease: A precursor of the metabolic syndrome
  37. Role of ultrasound in the diagnosis and treatment of nonalcoholic fatty liver disease and its complications
  38. Diagnosis and management of cardiovascular risk in nonalcoholic fatty liver disease
  39. Primary lymphoma of the spleen mimicking simple benign cysts: contrast-enhanced ultrasonography and other imaging findings
  40. Inflammatory hepatocellular adenomatosis, metabolic syndrome, polycystic ovary syndrome and non-alcoholic steatohepatitis: Chance tetrad or association by necessity?
  41. Cardiovascular risk, lipidemic phenotype and steatosis. A comparative analysis of cirrhotic and non-cirrhotic liver disease due to varying etiology
  42. Chronic hepatitis C virus infection and atherosclerosis: Clinical impact and mechanisms
  43. Nonalcoholic fatty liver disease and aging: Epidemiology to management
  44. Pathogenesis and significance of hepatitis C virus steatosis: An update on survival strategy of a successful pathogen
  45. Risk of cardiovascular, cardiac and arrhythmic complications in patients with non-alcoholic fatty liver disease
  46. From NAFLD in clinical practice to answers from guidelines
  47. Use of procalcitonin for the differential diagnosis of fever in cancer patients: an observational study
  48. Short-term multidisciplinary non-pharmacological intervention is effective in reducing liver fat content assessed non-invasively in patients with nonalcoholic fatty liver disease (NAFLD)
  49. Relationship of Serum Fetuin-A Levels with Coronary Atherosclerotic Burden and NAFLD in Patients Undergoing Elective Coronary Angiography
  50. Cardiovascular and Systemic Risk in Nonalcoholic Fatty Liver Disease - Atherosclerosis as a Major Player in the Natural Course of NAFLD
  51. HCV treatment in patients with metabolic syndrome
  52. Liver and diabetes. A vicious circle
  53. Potential for statins in the chemoprevention and management of hepatocellular carcinoma
  54. Hepatocellular carcinoma in a patient treated with efalizumab for psoriasis
  55. If steatosis is the atherosclerosis of the liver, are statins the “aspirin” for steatosis?
  56. Ultrasonographic fatty liver indicator, a novel score which rules out NASH and is correlated with metabolic parameters in NAFLD
  57. Chronic HCV infection is a risk of atherosclerosis. Role of HCV and HCV-related steatosis
  58. Human Immunodeficiency Virus Is the Major Determinant of Steatosis and Hepatitis C Virus of Insulin Resistance in Virus-associated Fatty Liver Disease
  59. Metabolic alterations and chronic hepatitis C: treatment strategies
  60. Treatment of Atherogenic Liver Based on the Pathogenesis of Nonalcoholic Fatty Liver Disease: A Novel Approach to Reduce Cardiovascular Risk?
  61. Nonalcoholic fatty liver disease activity score and Brunt's pathologic criteria for the diagnosis of nonalcoholic steatohepatitis: What do they mean and do they agree?
  62. Is nonalcoholic steatohepatitis associated with a high-though-normal thyroid stimulating hormone level and lower cholesterol levels?
  63. Insulin resistance in nonalcoholic steatohepatitis: necessary but not sufficient – death of a dogma from analysis of therapeutic studies?
  64. Perspectives on cellular dysfunction in nonalcoholic steatohepatitis: a case of ‘multiorganelle failure’? Proceedings of a virtual workshop on nonalcoholic steatohepatitis
  65. Clinical physiology of NAFLD: a critical overview of pathogenesis and treatment
  66. Practice guidelines for the diagnosis and management of nonalcoholic fatty liver disease
  67. Nonalcoholic Fatty Liver Disease in HIV-Infected Persons: Epidemiology and the Role of Nucleoside Reverse Transcriptase Inhibitors
  68. Genetic polymorphisms in non-alcoholic fatty liver disease: Interleukin-6−174G/C polymorphism is associated with non-alcoholic steatohepatitis
  69. NAFLD and Cardiovascular Risk: Direct Evidence for the Tale of Two Ages
  70. Differential effect of oleic and palmitic acid on lipid accumulation and apoptosis in cultured hepatocytes
  71. Endocrine and liver interaction: the role of endocrine pathways in NASH
  72. Hepatitis C and diabetes: the inevitable coincidence?
  73. Fatty Liver and Carotid Intimal Thickening: A Tale of Two Ages?
  74. Hepatitis C Virus-Infected Patients Are ‘Spared’ from the Metabolic Syndrome but Not from Insulin Resistance. A Comparative Study of Nonalcoholic Fatty Liver Disease and Hepatitis C Virus-Related Steatosis
  75. The hepatitis C virus-associated dysmetabolic syndrome
  76. Statins in liver disease: A molehill, an iceberg, or neither?
  77. Do diabetes and obesity promote hepatic fibrosis in familial heterozygous hypobetalipoproteinemia?
  78. Is liver fat detrimental to vessels?: intersections in the pathogenesis of NAFLD and atherosclerosis
  79. Dysmetabolic changes associated with HCV: a distinct syndrome?
  80. The neck-liver axis. Madelung disease as further evidence for an impact of body fat distribution on hepatic histology
  81. Non-alcoholic fatty liver disease (NAFLD) and cardiovascular disease: An open question
  82. HCV and diabetes
  83. Is Cholangiocarcinoma Another Complication of Insulin Resistance: A Report of Three Cases
  84. Chicken or egg turned into head or belly
  85. ‘Endocrine NAFLD’ a hormonocentric perspective of nonalcoholic fatty liver disease pathogenesis
  86. 17beta-estradiol prevents cytotoxicity from hydrophobic bile acids in HepG2 and WRL-68 cell cultures
  87. Hepatitis C and steatosis: a reappraisal
  88. Statins and HCV: A complex issue
  89. Gender, fatty liver and GGT
  90. Hepatic steatosis and insulin resistance: Does etiology make a difference?
  91. Fatty liver, carotid disease and gallstones: A study of age-related associations
  92. Review article: hepatic steatosis and insulin resistance
  93. Review article: the metabolic syndrome and non-alcoholic fatty liver disease
  94. Gallstone disease in non-alcoholic fatty liver: Prevalence and associated factors
  95. Pediatric gallstone disease in familial hypobetalipoproteinemia
  96. Should Nonalcoholic Fatty Liver Disease Be Renamed?
  97. The wide spectrum of steatohepatitis
  98. Steatosis and hepatitis C virus: Mechanisms and significance for hepatic and extrahepatic disease
  99. Relative contribution of iron burden, HFE mutations, and insulin resistance to fibrosis in nonalcoholic fatty liver
  100. Non-Organ-Specific Autoantibodies in Nonalcoholic Fatty Liver Disease: Prevalence and Correlates
  101. Intestinal Wegener's granulomatosis in a patient with severe alpha-1-antitrypsin deficiency resulting from a unique combination of two deficiency alleles (PiZ and PiMProcida)
  102. Apolipoprotein synthesis in nonalcoholic steatohepatitis
  103. Growth hormone plasma levels in nonalcoholic fatty liver disease
  104. Of liver, whisky and plants: a requiem for colchicine in alcoholic cirrhosis?
  105. Growth hormone plasma levels in nonalcoholic fatty liver disease
  106. Fasting insulin and uric acid levels but not indices of iron metabolism are independent predictors of non-alcoholic fatty liver disease. A case-control study
  107. Is insulin resistance a pathogenic co-factor in hepatitis C virus-related disease and hepatocellular carcinoma?
  108. A study of fatty liver disease and plasma lipoproteins in a kindred with familial hypobetalipoproteinemia due to a novel truncated form of apolipoprotein B (APO B-54.5)
  109. Are there any sex differences in fatty liver? A study of glucose metabolism and body fat distribution
  110. Fatty Liver and Nonalcoholic Steatohepatitis. Where Do We Stand and Where Are We Going?
  111. Isolated jejunal Crohn's disease in a young adult presenting as fever of unknown origin
  112. Fatty liver in heterozygous hypobetalipoproteinemia caused by a novel truncated form of apolipoprotein B
  113. LETTER TO THE EDITOR
  114. LETTER TO THE EDITOR
  115. Are Routine Duodenal and Antral Biopsies Useful in the Management of “Functional” Dyspepsia?
  116. Right Colon Adenocarcinoma Presenting as Bacteroides fragilis Liver Abscesses
  117. Solitary Peutz-Jeghers Type Polyp of the Stomach
  118. Liver cirrhosis as A diabetogenic condition
  119. Familial history in IBD